Moderna, Inc. (MUN:0QF)
| Market Cap | 8.06B |
| Revenue (ttm) | 1.90B |
| Net Income (ttm) | -2.66B |
| Shares Out | n/a |
| EPS (ttm) | -6.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 760 |
| Average Volume | 114 |
| Open | 19.34 |
| Previous Close | 19.50 |
| Day's Range | 19.26 - 20.69 |
| 52-Week Range | 19.26 - 46.34 |
| Beta | n/a |
| RSI | 43.43 |
| Earnings Date | Feb 20, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow
2025-11-22. The following slide deck was published by Moderna, Inc.
Piper Sandler Lowers Moderna (MRNA) Price Target to $63 | MRNA Stock News
Piper Sandler Lowers Moderna (MRNA) Price Target to $63 | MRNA Stock News
First Week of MRNA July 2026 Options Trading
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading this week, for the July 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the ...
Moderna (MRNA) Rating Maintained, Price Target Lowered by RBC Capital | MRNA Stock News
Moderna (MRNA) Rating Maintained, Price Target Lowered by RBC Capital | MRNA Stock News
Noteworthy Thursday Option Activity: JNJ, MRNA, ALB
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Johnson & Johnson (Symbol: JNJ), where a total volume of 39,084 contracts has been trad...
What's Going On With Moderna Stock?
Shares of Moderna, Inc. (NASDAQ: MRNA) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy . MRNA is lagging ...
Moderna (MRNA) Unveils Pipeline Progress and Strategic Updates at Analyst Day
Moderna (MRNA) Unveils Pipeline Progress and Strategic Updates at Analyst Day
Moderna Trims Pipeline and Takes On $1.5 Billion Loan as Cash Worries Loom
Moderna (MRNA) Projects Revenue Growth and Strategic Changes
Moderna (MRNA) Projects Revenue Growth and Strategic Changes
Moderna (MRNA) Optimizes Global Manufacturing for Future Growth
Moderna (MRNA) Optimizes Global Manufacturing for Future Growth
Moderna (MRNA) Targets Major Vaccine Expansion by 2028
Moderna (MRNA) Targets Major Vaccine Expansion by 2028
Moderna (MRNA) Reveals Strategic Plans for Growth and Innovation
Moderna (MRNA) Reveals Strategic Plans for Growth and Innovation
Moderna (MRNA) Projects Revenue Growth and Strategic Investments
Moderna (MRNA) Projects Revenue Growth and Strategic Investments
Moderna (MRNA) Developments: Vaccine Approvals and Strategic Adjustments
Moderna (MRNA) Developments: Vaccine Approvals and Strategic Adjustments
Moderna projects 10% growth next year; lifts outlook for year-end liquidity
Moderna (MRNA) Secures $1.5 Billion Loan to Boost Financial Flexibility
Moderna (MRNA) Secures $1.5 Billion Loan to Boost Financial Flexibility
Moderna (MRNA) Projects Revenue Growth and Strategic Financial Management
Moderna (MRNA) Projects Revenue Growth and Strategic Financial Management
Moderna (MRNA) Unveils Strategic Growth Plans and Pipeline Updates
Moderna (MRNA) Unveils Strategic Growth Plans and Pipeline Updates
Moderna (MRNA) Secures $1.5 Billion Loan to Enhance Financial Flexibility
Moderna (MRNA) Secures $1.5 Billion Loan to Enhance Financial Flexibility
Moderna takes $1.5 billion loan, expects 10% revenue growth next year
Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibilityCompany reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash br...
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine franchise from three to up to six approved products b...
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash b...
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...
Moderna (MRNA) Expands U.S. Manufacturing with $140M Investment
Moderna (MRNA) Expands U.S. Manufacturing with $140M Investment